Patents by Inventor David B. Olsen
David B. Olsen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240131028Abstract: The present invention relates to a method of chemovaccination against Plasmodium infection comprising administering to a patient an effective amount of a selective inhibitor of plasmepsin X, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: February 2, 2022Publication date: April 25, 2024Applicants: Merck Sharp & Dohme LLC, The Walter and Eliza Hall Institute of Medical ResearchInventors: Justin A. Boddey, David B. Olsen, Ryan Steel, John A. McCauley, Manuel De Lera Ruiz
-
Publication number: 20230355622Abstract: A method of chemovaccination against Plasmodium infections comprising administering to a patient, an effective amount of a dual inhibitor of plasmepsin IX and X, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: September 20, 2021Publication date: November 9, 2023Applicants: Merck Sharp & Dohme LLC, The Walter and Eliza Hall Institute of Medical ResearchInventors: Justin A. Boddey, David B. Olsen, Ryan Steel
-
Patent number: 11766435Abstract: The present invention provides methods of treating malaria comprising administration of an N3-substituted iminopyrimidinone of Formula (I) or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the variables R1, R2, R3, R4, R5, A, B, L, m, and n are as defined herein. The invention also provides uses of the compounds of Formula (I), as defined herein, for inhibiting plasmepsin V activity, for treating a Plasmodium infection, and for treating malaria. Also provided are methods of treatment further comprising administration of one or more additional anti-malarial compounds.Type: GrantFiled: February 13, 2017Date of Patent: September 26, 2023Assignees: Merck Sharp & Dohme LLC, The Walter and Eliza Hall Institute of Medical ResearchInventors: Tanweer A. Khan, Jared N. Cumming, David B. Olsen, Justin A. Boddey, Alan F. Cowman, Brad E. Sleebs
-
Publication number: 20230139282Abstract: Provided are methods of treating malaria comprising administration of compounds of Formula (I) or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the variables are as defined herein. Also provided are uses of the compounds of Formula (I), as defined herein, for treating a Plasmodium infection, and for treating malaria. Also provided are methods of treatment further comprising administration of one or more additional anti-malarial compounds.Type: ApplicationFiled: February 2, 2021Publication date: May 4, 2023Applicants: Merck Sharp & Dohme LLC, The Walter and Eliza Hall Institute of Medical Research, MSD R&D (China) Co., Ltd.Inventors: Manuel de Lera Ruiz, Paola Favuzza, Zhuyan Guo, Bin Hu, Michael J. Kelly, III, Zhiyu Lei, John A. McCauley, David B. Olsen, Brad Sleebs, Tony Triglia, Dongmei Zhan, Lianyun Zhao
-
Publication number: 20230013692Abstract: The present invention provides methods of treating malaria comprising administration of compounds of Formula (I) or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the variables are as defined herein. The invention also provides uses of the compounds of Formula (I), as defined herein, for the possible inhibition of plasmepsin X, plasmepsin IX or plasmepsin X and IX activity, for treating a Plasmodium infection, and for treating malaria. Also provided are methods of treatment further comprising administration of one or more additional anti-malarial compounds.Type: ApplicationFiled: November 16, 2020Publication date: January 19, 2023Applicants: Merck Sharp & Dohme LLC, MSD R&D (China) Co. Ltd., The Walter and Eliza Hall Institute of Medical ResearchInventors: John A. McCauley, Manuel de Lera Ruiz, Zhuyan Guo, Bin Hu, Michael J. Kelly, III, Zhiyu Lei, David B. Olsen, Brad Sleebs, Dongmei Zhan, Lianyun Zhao
-
Publication number: 20220331321Abstract: Methods of treating malaria comprising administration of compounds of Formula (I?) or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the variables are as defined herein. It also provides uses of the compounds of Formula (I), as defined herein, for inhibiting plasmepsin X, plasmepsin IX or plasmepsin X and IX activity, for treating a Plasmodium infection, and for treating malaria. Also provided are methods of treatment further comprising administration of one or more additional anti-malarial compounds.Type: ApplicationFiled: July 21, 2020Publication date: October 20, 2022Applicants: Merck Sharp & Dohme Corp., The Walter and Eliza Hall Institute of Medical Research, MSD R & D (China) Co. LTD.Inventors: John A. McCauley, Alan F. Cowman, Manuel de Lera Ruiz, Paola Favuzza, Zhuyan Guo, Bin Hu, Michael J. Kelly, III, Zhiyu Lei, David B. Olsen, Brad Sleebs, Jennifer K. Thompson, Tony Triglia, Dongmei Zhan, Cailing Zhang, Lianyun Zhao
-
Publication number: 20220081403Abstract: The present invention discloses oxazolidinone compounds of Formula (I): (I) and pharmaceutically acceptable salts thereof, wherein A and E, are as defined herein. The present invention also relates to compositions which comprise at least one oxazolidinone compound of the invention. The invention also provides methods for inhibiting growth of mycobacterial cells as well as a method of treating mycobacterial infections by Mycobacterium tuberculosis comprising administering a therapeutically effective amount of an oxazolidinone of the invention and/or a pharmaceutically acceptable salt thereof, or a composition comprising such compound and/or salt.Type: ApplicationFiled: December 19, 2019Publication date: March 17, 2022Applicant: Merck Sharp & Dohme Corp.Inventors: Randall R. Miller, Joseph A. Kozlowski, Philippe Nantermet, David B. Olsen, Jing Su, Lihu Yang, Takao Suzuki, Brendan Crowley, Negxue Wang, Lanying You
-
Publication number: 20210379020Abstract: The present invention provides methods of treating malaria by administration of a compound of Formula (I): or a pharmaceutically acceptable salt of said compound, to a subject in need thereof, wherein the variables X, R1, R3, R4, R5, A, B, L, m and n are as defined herein. The invention also provides uses of the compounds of Formula (I), as defined herein, for inhibiting plasmepsin V activity, for treating a Plasmodium infection, and for treating malaria. Also provided are methods of treatment further comprising administration of one or more additional anti-malarial compounds.Type: ApplicationFiled: August 11, 2021Publication date: December 9, 2021Applicants: Merck Sharp & Dohme Corp., The Walter and Eliza Hall Institute of Medical ResearchInventors: Tanweer A. Khan, Jared N. Cumming, David B. Olsen, Justin A. Boddey, Alan F. Cowman, Brad E. Sleebs
-
Patent number: 10947205Abstract: The present invention relates to oxazolidinone compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, E, and R1 are as defined herein. The present invention also relates to compositions which comprise at least one oxazolidinone compound of the invention. The invention also provides methods for inhibiting growth of mycobacterial cells as well as a method of treating mycobacterial infections by Mycobacterium tuberculosis comprising administering a therapeutically effective amount of an oxazolidinone of the invention and/or a pharmaceutically acceptable salt thereof, or a composition comprising such compound and/or salt.Type: GrantFiled: April 29, 2019Date of Patent: March 16, 2021Assignee: Merck Sharp & Dohme Corp.Inventors: Mihir B. Mandal, David B. Olsen, Jing Su, Lihu Yang, Katherine Young, Takao Suzuki, Lanying You
-
Publication number: 20210061777Abstract: The present invention relates to oxazolidinone compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, E, and R1 are as defined herein. The present invention also relates to compositions which comprise at least one oxazolidinone compound of the invention. The invention also provides methods for inhibiting growth of mycobacterial cells as well as a method of treating mycobacterial infections by Mycobacterium tuberculosis comprising administering a therapeutically effective amount of an oxazolidinone of the invention and/or a pharmaceutically acceptable salt thereof, or a composition comprising such compound and/or salt.Type: ApplicationFiled: November 10, 2020Publication date: March 4, 2021Applicant: Merck Sharp & Dohme Corp.Inventors: Mihir B. Mandal, David B. Olsen, Jing Su, Lihu Yang, Katherine Young, Takao Suzuki, Lanying You
-
Publication number: 20200230140Abstract: The present invention provides methods of treating malaria comprising administration of an N3-substituted iminopyrimidinone of Formula (I) or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the variables R1, R2, R3, R4, R5, A, B, L, m, and n are as defined herein. The invention also provides uses of the compounds of Formula (I), as defined herein, for inhibiting plasmepsin V activity, for treating a Plasmodium infection, and for treating malaria. Also provided are methods of treatment further comprising administration of one or more additional anti-malarial compounds.Type: ApplicationFiled: February 13, 2017Publication date: July 23, 2020Applicants: Merck Sharp & Dohme Corp., The Walter and Eliza Hall Institute of Medical ResearchInventors: Tanweer A. Khan, Jared N. Cumming, David B. Olsen, Justin A. Boddey, Alan F. Cowman, Brad E. Sleebs
-
Publication number: 20200223220Abstract: The present invention provides methods of treating malaria by administration of a compound of Formula (I): or a pharmaceutically acceptable salt of said compound, to a subject in need thereof, wherein the variables X, R1, R3, R4, R5, A, B, L, m and n are as defined herein. The invention also provides uses of the compounds of Formula (I), as defined herein, for inhibiting plasmepsin V activity, for treating a Plasmodium infection, and for treating malaria. Also provided are methods of treatment further comprising administration of one or more additional anti-malarial compounds.Type: ApplicationFiled: March 24, 2020Publication date: July 16, 2020Applicants: Merck Sharp & Dohme Corp., The Walter and Eliza Hall Institute of Medical ResearchInventors: Tanweer A. Khan, Jared N. Cumming, David B. Olsen, Justin A. Boddey, Alan F. Cowman, Brad E. Sleebs
-
Publication number: 20190248753Abstract: The present invention relates to oxazolidinone compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, E, and R1 are as defined herein. The present invention also relates to compositions which comprise at least one oxazolidinone compound of the invention. The invention also provides methods for inhibiting growth of mycobacterial cells as well as a method of treating mycobacterial infections by Mycobacterium tuberculosis comprising administering a therapeutically effective amount of an oxazolidinone of the invention and/or a pharmaceutically acceptable salt thereof, or a composition comprising such compound and/or salt.Type: ApplicationFiled: April 29, 2019Publication date: August 15, 2019Inventors: Mihir B. Mandal, David B. Olsen, Jing Su, Lihu Yang, Katherine Young, Takao Suzuki, Lanying You
-
Publication number: 20190046507Abstract: The present invention provides methods of treating malaria by administration of a compound of Formula (I): or a pharmaceutically acceptable salt of said compound, to a subject in need thereof, wherein the variables X, R1, R3, R4, R5, A, B, L, m and n are as defined herein. The invention also provides uses of the compounds of Formula (I), as defined herein, for inhibiting plasmepsin V activity, for treating a Plasmodium infection, and for treating malaria. Also provided are methods of treatment further comprising administration of one or more additional anti-malarial compounds.Type: ApplicationFiled: February 13, 2017Publication date: February 14, 2019Applicants: Merck Sharp & Dohme Corp., The Walter and Eliza Hall Institute of Medical ResearchInventors: Tanweer A. Khan, Jared N. Cumming, David B. Olsen, Justin A. Boddey, Alan F. Cowman, Brad E. Sleebs
-
Patent number: 10144741Abstract: The present invention relates to novel nargenicin related compounds which can inhibit DnaE and have antibacterial, particularly antimycobacterial activity against Mycobacterium tuberculosis. The present invention also relates to method for inhibiting growth of mycobacterial cells as well as a method of treating mycobacterial infections by Mycobacterium tuberculosis by administering an antimycobacterially effective amount of nargenicin or a nargenicin-related compound and/or their pharmaceutically acceptable salts.Type: GrantFiled: March 2, 2018Date of Patent: December 4, 2018Assignee: Merck Sharp & Dohme Corp.Inventors: Katherine Young, David B. Olsen, Sheo B. Singh, Jing Su, Robert R. Wilkening, James M. Apgar, Dongfang Meng, Dann Parker, Mihir Mandal, Lihu Yang, Ronald E. Painter, Qun Dang, Takao Suzuki
-
Publication number: 20180290987Abstract: The present invention relates to oxazolidinone compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, E, and R1 are as defined herein. The present invention also relates to compositions which comprise at least one oxazolidinone compound of the invention. The invention also provides methods for inhibiting growth of mycobacterial cells as well as a method of treating mycobacterial infections by Mycobacterium tuberculosis comprising administering a therapeutically effective amount of an oxazolidinone of the invention and/or a pharmaceutically acceptable salt thereof, or a composition comprising such compound and/or salt.Type: ApplicationFiled: October 17, 2016Publication date: October 11, 2018Inventors: Mihir B. Mandal, David B. Olsen, Jing Su, Lihu Yang, Katherine Young, Takao Suzuki, Lanying You
-
Publication number: 20180186808Abstract: The present invention relates to novel nargenicin related compounds which can inhibit DnaE and have antibacterial, particularly antimycobacterial activity against Mycobacterium tuberculosis. The present invention also relates to method for inhibiting growth of mycobacterial cells as well as a method of treating mycobacterial infections by Mycobacterium tuberculosis by administering an antimycobacterially effective amount of nargenicin or a nargenicin-related compound and/or their pharmaceutically acceptable salts.Type: ApplicationFiled: March 2, 2018Publication date: July 5, 2018Inventors: Katherine Young, David B. Olsen, Sheo B. Singh, Jing Su, Robert R. Wilkening, James M. Apgar, Dongfang Meng, Dann Parker, Mihir Mandal, Lihu Yang, Ronald E. Painter, Qun Dang, Takao Suzuki
-
Patent number: 9944654Abstract: The present invention relates to novel nargenicin related compounds which can inhibit DnaE and have antibacterial, particularly antimycobacterial activity against Mycobacterium tuberculosis. The present invention also relates to method for inhibiting growth of mycobacterial cells as well as a method of treating mycobacterial infections by Mycobacterium tuberculosis by administering an antimycobacterially effective amount of nargenicin or a nargenicin-related compound and/or their pharmaceutically acceptable salts.Type: GrantFiled: October 21, 2015Date of Patent: April 17, 2018Assignee: Merck Sharp & Dohme Corp.Inventors: Katherine Young, David B. Olsen, Sheo B. Singh, Jing Su, Robert R. Wilkening, James M. Apgar, Dongfang Meng, Dann Parker, Mihir Mandal, Lihu Yang, Ronald E. Painter, Qun Dang, Takao Suzuki
-
Publication number: 20180002366Abstract: The present invention is directed to 4?-substituted nucleoside derivatives of Formula I and their use in the inhibition of HIV reverse transcriptase, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the prophylaxis, treatment, and delay in the onset or progression of AIDS and/or ARC.Type: ApplicationFiled: August 24, 2017Publication date: January 4, 2018Applicant: MERCK SHARP & DOHME CORP.Inventors: Vinay M. Girijavallabhan, David B. Olsen, Zhibo Zhang, Jianmin Fu, Bing-Yu Tang
-
Publication number: 20170305924Abstract: The present invention relates to novel nargenicin related compounds which can inhibit DnaE and have antibacterial, particularly antimycobacterial activity against Mycobacterium tuberculosis. The present invention also relates to method for inhibiting growth of mycobacterial cells as well as a method of treating mycobacterial infections by Mycobacterium tuberculosis by administering an antimycobacterially effective amount of nargenicin or a nargenicin-related compound and/or their pharmaceutically acceptable salts.Type: ApplicationFiled: October 21, 2015Publication date: October 26, 2017Applicant: Merck Sharp & Dohme Corp.Inventors: Katherine Young, David B. Olsen, Sheo B. Singh, Jing Su, Robert R. Wilkening, James M. Apgar, Dongfang Meng, Dann Parker, Mihir Mandal, Lihu Yang, Ronald E. Painter, Qun Dang, Takao Suzuki